An algorithmic approach to the diagnosis and management of the thrombotic microangiopathies

American Journal of Clinical Pathology

Volumn 145, Issue 2, 2016, Pages 152-154

  Bendapudi, Pavan K ^a,b   Makar, Robert S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE KIDNEY FAILURE; ATYPICAL UREMIC SYNDROME; ENZYME ACTIVITY; HEMOLYTIC UREMIC SYNDROME; HUMAN; ORGAN INJURY; PHYSICIAN; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; THROMBOTIC THROMBOCYTOPENIC PURPURA; DIFFERENTIAL DIAGNOSIS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOTIC MICROANGIOPATHIES;

EID: 84959324744     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1093/AJCP/AQW003     Document Type: Review

References (23)

1. Williams LA, Marques MB. Pathology consultation on the diagnosis and treatment of thrombotic microangiopathies (TMAs). Am J Clin Pathol. 2016;145:158-165.
2. George JN, Nester CM. Syndromes of thrombotic microangi-opathy. N Engl J Med. 2014;371:654-666.
3. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393-397.
4. Bendapudi PK, Li A, Hamdan A, et al. Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative. Br J Haematol. 2015;171:836-844.
5. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169-2181.
6. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267-1279.
7. Rice TW, Wheeler AP. Coagulopathy in critically ill patients: part 1: platelet disorders. Chest. 2009;136:1622-1630.
8. Seguin P, Roquilly A, Mimoz O, et al. Risk factors and outcomes for prolonged versus brief fever: a prospective cohort study. Crit Care. 2012;16:R150.
9. Burns ER, Lou Y, Pathak A. Morphologic diagnosis of throm-botic thrombocytopenic purpura. Am J Hematol. 2004;75:18-21.
10. Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol. 2009;5:210-220.
11. Murugan R, Kellum JA. Acute kidney injury: what's the prognosis? Nat Rev Nephrol. 2011;7:209-217.
12. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45:139-159.
13. Sadler JE. What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Hematol Am Soc Hematol Educ Program. 2015;2015:631-636.
14. Shah N, Rutherford C, Matevosyan K, et al. Role of ADAMTS13 in the management of thrombotic microangio-pathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol. 2013;163:514-519.
15. Hassan S, Westwood JP, Ellis D, et al. The utility of ADAMTS13 in differentiating TTP from other acute throm-botic microangiopathies: results from the UK TTP Registry. Br J Haematol. 2015;171:830-835.
16. Bendapudi PK, Li A, Hamdan A, et al. Derivation and prospective validation of a predictive score for the rapid diagnosis of thrombotic thrombocytopenic purpura: the PLASMIC score. Blood. 2014;124:231.
17. Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One. 2010;5:e10208.
18. Bentley MJ, Lehman CM, Blaylock RC, et al. The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange. Transfusion. 2010;50:1654-1664.
19. Li A, Makar RS, Hurwitz S, et al. Therapeutic plasma exchange for the treatment of thrombotic microangiopathy without severe ADAMTS13 deficiency: a propensity score-matched study. Blood. 2015;126:3471.
20. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676-1687.
21. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759-765.
22. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic ur-emic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60-68.
23. George JN. Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why? Transfusion. 2015;55:11-13.